Irritable Bowel Syndrome Clinical Trial
Official title:
Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients With Irritable Bowel Syndrome: a Double-blind, Randomized, Placebo-controlled Trial
The purpose of this study is to assess the efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome (IBS) or IBS/functional dyspepsia (FD).
Using a random number generator, 56 patients meeting inclusion criteria with IBS or IBS/FD
were randomly assigned to either the intervention group (28 individuals) or the control group
(28 individuals) (Table 2). Non-functional causes for the symptoms were excluded by a
detailed evaluation of the medical history, physical examination, extensive panel of blood
tests, stool analysis, and colonoscopy with biopsies.
Diarrhoea-predominant IBS patients (IBS-D) and mixed bowel habits IBS patients (IBS-M) were
treated with smooth muscle antispasmodics. The constipation-predominant IBS patients (IBS-C)
were treated with smooth muscle antispasmodics and laxatives. IBS/FD patients were treated
with smooth muscle antispasmodics and proton pump inhibitors.
At Visit 1, all patients were randomly assigned into two groups. In the intervention group
(Group 1), the supplement "Standart Zdorovya GASTRO" (1 capsule, 730 mg, once a day) was
added to the standard treatment regimen for 30 days. In the control group (Group 2), placebo
(1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days
(Table 1). Researchers and patients were not informed who received a supplement or placebo.
During the 30 days of the study, three outpatient visits were conducted (Visit 1 - Day 1,
Visit 2 - Day 15 + 2 days, and Visit 3 - Day 30 + 2 days).
Symptom severity was assessed on each visit using "7x7" questionnaire [Ivashkin, V.,
Sheptulin, A., Shifrin, O., Poluektova, E., Pavlov, C., Ivashkin, K., Drozdova, A.,
Lyashenko, O., Korolev, A., 2019. Clinical validation of the "7 × 7" questionnaire for
patients with functional gastrointestinal disorders. J. Gastroenterol. Hepatol. 34,
1042-1048. https://doi.org/10.1111/jgh.14546], on 1 and 3 visits stool samples were collected
for the qualitative and quantitative composition of the intestinal microbiota based on 16S
rRNA gene sequencing.
The study protocol was approved by the Ethics Committee of the Mental Health Research Center,
Moscow, Russian Federation (No. 418 dated 01/31/2018) and written informed consent was
obtained from all participants.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
| Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
| Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
| Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
| Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
| Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
| Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
| Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
| Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
| Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
| Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
| Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
| Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
| Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
| Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
| Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
| Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
| Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |